BMY 58.61 Bristol-Myers Squibb Company $BMY Hit a
Post# of 115
Posted On: 11/12/2014 10:33:31 AM
BMY 58.61 Bristol-Myers Squibb Company $BMY Hit a 52 week high of 58.68 Closing the day 09:45 at 58.61 -0.11 -0.19% With a day low of 58.46 and a total volume of 241,052.
BMY Recent Posts: http://investorshangout.com/Bristol-Myers-Squ...BMY-50337/
BMY Bristol-Myers Squibb Company Recent Headline News
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting
Business Wire - 1 hr 56 mins ago
--Real-world data highlighting meaningful patient-reported outcomes and reinforcing the established safety data of Orencia
BMY: 58.60 (-0.12)
Food Allergy Global Clinical Trials Review, H2, 2014
M2 - Wed Nov 12, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjd7jz/food_allergy) has announced the addition of the "Food Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Food Allergy Global Clinical Trials Review, H2, 2014" provides data on the Food Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Food Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Food Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Food Allergy Therapeutics Clinical Trials - United Pharmaceuticals SA - DBV Technologies SA - Mead Johnson Nutrition Company - Danone Research B.V. - Friesland Coberco Dairy Foods Holding N.V. - Danone SA - Cosmetique Active International S.N.C. - Bristol-Myers Squibb Company - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Federico II University - Mount Sinai Hospital - Nambudripad's Allergy Research Foundation - Stanford University - Helsinki University Central Hospital - National Center for Child Health and Development - Osaka Prefectural Medical Center for Respiratory and Allergic Diseases - The University of North Carolina at Chapel Hill - Murdoch Childrens Research Institute For more information visit http://www.researchandmarkets.com/research/cj...od_allergy
MJN: 99.49 (+0.23), DBVT: 23.91 (-0.34), BMY: 58.60 (-0.12)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.68 (+2.34), GILD: 106.14 (-1.87), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.78 (-0.13), BAX: 70.86 (+0.10), PFE: 30.40 (+0.08), BMY: 58.60 (-0.12)
Bristol-Myers Squibb's (BMY) CFO Charlie Banccroft on Credit Suisse Healthcare Conference - Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:43PM CST
BMY: 58.60 (-0.12)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.78 (-0.13), BAX: 70.86 (+0.10), PFE: 30.40 (+0.08), BMY: 58.60 (-0.12)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 106.15 (-1.86), ACHN: 13.00 (+0.52), MRK: 59.41 (+0.04), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.78 (-0.13), GILD: 106.14 (-1.87), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), MRK: 59.41 (+0.04), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 116.13 (-1.36), GILD: 106.14 (-1.87), MRK: 59.41 (+0.04), DNDN: 0.16 (+0.01), AZN: 74.28 (+0.08), TEVA: 58.25 (+0.06), ABBV: 63.82 (-0.03), GSK: 45.76 (-0.20), BMY: 58.60 (-0.12), NVS: 93.05 (+0.28)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.78 (-0.13), BAX: 70.86 (+0.10), PFE: 30.40 (+0.08), BMY: 58.60 (-0.12)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.78 (-0.13), GILD: 106.14 (-1.87), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), MRK: 59.41 (+0.04), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.78 (-0.13), GILD: 106.14 (-1.87), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), MRK: 59.41 (+0.04), LGND: 56.70 (-0.20), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.78 (-0.13), GILD: 106.15 (-1.86), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), LGND: 56.70 (-0.20), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 11, 7:52AM CST
It's hard for any new hepatitis C drugs to compete with Gilead Sciences ' Harvoni, with its cure rate topping 95%, especially when you consider that some of those uncured patients are the inevitable dropouts who can be found in every clinical...
GILD: 106.15 (-1.86), MRK: 59.41 (+0.04), BMY: 58.60 (-0.12)
Five Prime Therapeutics Announces Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:20PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ending September 30, 2014.
BMY: 58.60 (-0.12), FPRX: 14.27 (+0.18)
Earnings Look Back: Bristol-Myers Squibb Is Up 8.7% Since Reporting Quarterly Results 2 Weeks Ago (BMY)
Comtex SmarTrend(R) - Mon Nov 10, 11:32AM CST
17 days ago, on October 24th, 2014, Bristol-Myers Squibb (NYSE:BMY) reported its earnings. Analysts, on average, expected earnings of $0.42 per share on sales of $3.8 billion. The company actually reported EPS of $0.45 on sales of $3.9 billion, beating EPS estimates by $0.03 and beating revenue estimates by $105.0 million. Shares of Bristol-Myers Squibb have climbed from $53.63 to $58.32, representing a gain of 8.7% since the company reported earnings 17 days ago.
BMY: 58.60 (-0.12)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.75 (+0.11), CRIS: 1.32 (+0.03), IMMU: 3.77 (unch), PCYC: 136.57 (+2.28), ONCY: 0.85 (+0.04), PFE: 30.40 (+0.08), LLY: 67.20 (-0.65), BMY: 58.60 (-0.12), GSK: 45.76 (-0.20), JNJ: 108.78 (-0.13), SNTA: 3.27 (+0.02), NVS: 93.05 (+0.28), XLRN: 32.29 (-1.43), ARRY: 3.81 (-0.03), CELGZ: 3.18 (-0.03), EXEL: 1.73 (-0.04)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.63 (+0.01), IMGN: 9.95 (-0.15), AMGN: 161.98 (-0.44), LLY: 67.20 (-0.65), ONTX: 4.77 (-0.08), BMY: 58.60 (-0.12), GSK: 45.76 (-0.20), OXGN: 1.77 (-0.15), XLRN: 32.29 (-1.43), KPTI: 43.00 (unch), NVS: 93.05 (+0.28)
Insider Trading Alert - PX, CDW And BMY Traded By Insiders
at The Street - Mon Nov 10, 10:15AM CST
Stocks with insider trader activity include PX, CDW and BMY
BMY: 58.60 (-0.12), PX: 126.61 (-0.09), CDW: 32.55 (-0.04)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.78 (-0.13), GILD: 106.15 (-1.86), ACHN: 12.99 (+0.51), MRK: 59.40 (+0.03), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12)
BMY Recent Posts: http://investorshangout.com/Bristol-Myers-Squ...BMY-50337/
BMY Bristol-Myers Squibb Company Recent Headline News
Bristol-Myers Squibb to Present Sixteen Orencia (abatacept) Data Abstracts at The American College of Rheumatology (ACR) 2014 Annual Meeting
Business Wire - 1 hr 56 mins ago
--Real-world data highlighting meaningful patient-reported outcomes and reinforcing the established safety data of Orencia
BMY: 58.60 (-0.12)
Food Allergy Global Clinical Trials Review, H2, 2014
M2 - Wed Nov 12, 5:21AM CST
Research and Markets (http://www.researchandmarkets.com/research/cjd7jz/food_allergy) has announced the addition of the "Food Allergy Global Clinical Trials Review, H2, 2014" report to their offering. Food Allergy Global Clinical Trials Review, H2, 2014" provides data on the Food Allergy clinical trial scenario. This report provides elemental information and data relating to the clinical trials on Food Allergy. It includes an overview of the trial numbers and their recruitment status as per the site of trial conduction across the globe. The databook offers a preliminary coverage of disease clinical trials by their phase, trial status, prominence of the sponsors and also provides briefing pertaining to the number of trials for the key drugs for treating Food Allergy. Scope - Data on the number of clinical trials conducted in North America, South and Central America, Europe, Middle-East and Africa and Asia-pacific and top five national contributions in each - Clinical trial (complete and in progress) data by phase, trial status, subjects recruited and sponsor type - Listings of discontinued trials (suspended, withdrawn and terminated) Top Companies Participating in Food Allergy Therapeutics Clinical Trials - United Pharmaceuticals SA - DBV Technologies SA - Mead Johnson Nutrition Company - Danone Research B.V. - Friesland Coberco Dairy Foods Holding N.V. - Danone SA - Cosmetique Active International S.N.C. - Bristol-Myers Squibb Company - Allertein Therapeutics, LLC Clinical Trial Overview of Top Institutes / Government - The National Institute of Allergy and Infectious Diseases - Federico II University - Mount Sinai Hospital - Nambudripad's Allergy Research Foundation - Stanford University - Helsinki University Central Hospital - National Center for Child Health and Development - Osaka Prefectural Medical Center for Respiratory and Allergic Diseases - The University of North Carolina at Chapel Hill - Murdoch Childrens Research Institute For more information visit http://www.researchandmarkets.com/research/cj...od_allergy
MJN: 99.49 (+0.23), DBVT: 23.91 (-0.34), BMY: 58.60 (-0.12)
Bristol-Myers Gives Updates on HCV Candidate Daclatasvir - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Tue Nov 11, 5:41PM CST
Bristol-Myers Squibb Company (BMY) provided an update on its hepatitis C (HCV) candidate daclatasvir.
AGN: 197.68 (+2.34), GILD: 106.14 (-1.87), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12)
Final Glance: Pharmaceuticals companies
AP - Tue Nov 11, 5:02PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies were mixed at the close of trading:
JNJ: 108.78 (-0.13), BAX: 70.86 (+0.10), PFE: 30.40 (+0.08), BMY: 58.60 (-0.12)
Bristol-Myers Squibb's (BMY) CFO Charlie Banccroft on Credit Suisse Healthcare Conference - Transcript
SA Transcripts - at Seeking Alpha - Tue Nov 11, 4:43PM CST
BMY: 58.60 (-0.12)
Midday Glance: Pharmaceuticals companies
AP - Tue Nov 11, 12:52PM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 1 p.m.:
JNJ: 108.78 (-0.13), BAX: 70.86 (+0.10), PFE: 30.40 (+0.08), BMY: 58.60 (-0.12)
Why Is Gilead Always Holding The Ace? A Prediction Of The Future HCV Market And What Analysts Aren't Talking About
Pharma Doc - Seeking Alpha - Tue Nov 11, 10:13AM CST
No matter when you've followed Gilead (NASDAQ: GILD ) over the past decade, they always seem to be holding the ace. Whether in the HIV arena or now in HCV, the Gilead management is always one step ahead and is planning to dominate its market. Gilead...
GILD: 106.15 (-1.86), ACHN: 13.00 (+0.52), MRK: 59.41 (+0.04), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12)
Gilead presents Harvoni data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 10:03AM CST
JNJ: 108.78 (-0.13), GILD: 106.14 (-1.87), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), MRK: 59.41 (+0.04), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Are Expensive Biotech Drugs Bad For Business?
Keith Williams - at Seeking Alpha - Tue Nov 11, 9:45AM CST
VRTX: 116.13 (-1.36), GILD: 106.14 (-1.87), MRK: 59.41 (+0.04), DNDN: 0.16 (+0.01), AZN: 74.28 (+0.08), TEVA: 58.25 (+0.06), ABBV: 63.82 (-0.03), GSK: 45.76 (-0.20), BMY: 58.60 (-0.12), NVS: 93.05 (+0.28)
Early Glance: Pharmaceuticals companies
AP - Tue Nov 11, 10:17AM CST
NEW YORK (AP) — Shares of some top pharmaceuticals companies are mixed at 10 a.m.:
JNJ: 108.78 (-0.13), BAX: 70.86 (+0.10), PFE: 30.40 (+0.08), BMY: 58.60 (-0.12)
AbbVie presents HCV/HIV and liver transplant HCV data
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 9:07AM CST
JNJ: 108.78 (-0.13), GILD: 106.14 (-1.87), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), MRK: 59.41 (+0.04), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Merck presents data from its investigational HCV combo
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:37AM CST
JNJ: 108.78 (-0.13), GILD: 106.14 (-1.87), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), MRK: 59.41 (+0.04), LGND: 56.70 (-0.20), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Gilead presents data from three HCV drug combo studies
Seeking Alpha - at Seeking Alpha - Tue Nov 11, 8:05AM CST
JNJ: 108.78 (-0.13), GILD: 106.15 (-1.86), ACHN: 13.00 (+0.52), CNAT: 6.87 (-0.19), LGND: 56.70 (-0.20), RGLS: 20.22 (-0.25), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12), ENTA: 43.18 (-0.04)
Gilead Sciences Inc. Breathes a Sigh of Relief -- Hepatitis C Patients, Not So Much
Brian Orelli, The Motley Fool - Motley Fool - Tue Nov 11, 7:52AM CST
It's hard for any new hepatitis C drugs to compete with Gilead Sciences ' Harvoni, with its cure rate topping 95%, especially when you consider that some of those uncured patients are the inevitable dropouts who can be found in every clinical...
GILD: 106.15 (-1.86), MRK: 59.41 (+0.04), BMY: 58.60 (-0.12)
Five Prime Therapeutics Announces Third Quarter 2014 Financial Results
GlobeNewswire - Mon Nov 10, 3:20PM CST
Five Prime Therapeutics, Inc. (Nasdaq:FPRX), a clinical-stage biotechnology company focused on discovering and developing novel protein therapeutics for cancer and inflammatory diseases, today provided a corporate update and reported financial results for the third quarter ending September 30, 2014.
BMY: 58.60 (-0.12), FPRX: 14.27 (+0.18)
Earnings Look Back: Bristol-Myers Squibb Is Up 8.7% Since Reporting Quarterly Results 2 Weeks Ago (BMY)
Comtex SmarTrend(R) - Mon Nov 10, 11:32AM CST
17 days ago, on October 24th, 2014, Bristol-Myers Squibb (NYSE:BMY) reported its earnings. Analysts, on average, expected earnings of $0.42 per share on sales of $3.8 billion. The company actually reported EPS of $0.45 on sales of $3.9 billion, beating EPS estimates by $0.03 and beating revenue estimates by $105.0 million. Shares of Bristol-Myers Squibb have climbed from $53.63 to $58.32, representing a gain of 8.7% since the company reported earnings 17 days ago.
BMY: 58.60 (-0.12)
Global Relapsed Multiple Myeloma Therapeutics Pipeline Report H2 2014 - Analysis of 43 Companies & 71 Drug Profiles
M2 - Mon Nov 10, 10:48AM CST
Research and Markets (http://www.researchandmarkets.com/research/hfth47/relapsed_multiple) has announced the addition of the "Relapsed Multiple Myeloma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Relapsed Multiple Myeloma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Relapsed Multiple Myeloma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Johnson & Johnson - F. Hoffmann-La Roche Ltd. - Sanofi - Eli Lilly and Company - GlaxoSmithKline plc - Biotest AG - Piramal Enterprises Limited - Prolexys Pharmaceuticals, Inc. - Millennium Pharmaceuticals, Inc. - Novartis AG - Astellas Pharma Inc. - Pfizer Inc. - Astex Pharmaceuticals, Inc. - Exelixis, Inc. - Celgene Corporation - Onyx Pharmaceuticals, Inc. - Immunomedics, Inc. - Cellectar Biosciences, Inc. - Oncolytics Biotech Inc. - Patrys Limited - Curis, Inc. - Pharmacyclics, Inc. - Array BioPharma Inc. - MorphoSys AG - Sevion Therapeutics, Inc. - Threshold Pharmaceuticals, Inc. - Synta Pharmaceuticals Corp. - Chroma Therapeutics Ltd. - Acceleron Pharma, Inc. For more information visit http://www.researchandmarkets.com/research/hf...d_multiple
CLRB: 2.75 (+0.11), CRIS: 1.32 (+0.03), IMMU: 3.77 (unch), PCYC: 136.57 (+2.28), ONCY: 0.85 (+0.04), PFE: 30.40 (+0.08), LLY: 67.20 (-0.65), BMY: 58.60 (-0.12), GSK: 45.76 (-0.20), JNJ: 108.78 (-0.13), SNTA: 3.27 (+0.02), NVS: 93.05 (+0.28), XLRN: 32.29 (-1.43), ARRY: 3.81 (-0.03), CELGZ: 3.18 (-0.03), EXEL: 1.73 (-0.04)
Head And Neck Cancer Squamous Cell Carcinoma Therapeutics Pipeline Report 2014 - 32 Companies & 65 DRug Profiles
M2 - Mon Nov 10, 10:26AM CST
Research and Markets (http://www.researchandmarkets.com/research/wml9ch/head_and_neck) has announced the addition of the "Head And Neck Cancer Squamous Cell Carcinoma - Pipeline Review, H2 2014" report to their offering. This report provides comprehensive information on the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Head And Neck Cancer Squamous Cell Carcinoma and special features on late-stage and discontinued projects. The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products. Companies Involved in Therapeutics Development - Bristol-Myers Squibb Company - Boehringer Ingelheim GmbH - F. Hoffmann-La Roche Ltd. - Shionogi & Co., Ltd. - Amgen Inc. - Eli Lilly and Company - GlaxoSmithKline plc - Celltrion, Inc. - Novartis AG - Eisai Co., Ltd. - ImmunoGen, Inc. - Santaris Pharma A/S - CEL-SCI Corporation - OXiGENE, Inc. - Takara Bio Inc. - Panacea Biotec Limited - PCI Biotech AS - Nanobiotix - Acceleron Pharma, Inc. - Virttu Biologics Limited - Ascenta Therapeutics, Inc. - Onconova Therapeutics, Inc. - Genexine, Inc. - Viventia Biotechnologies Inc. - Oncovir, Inc. - Gliknik, Inc. - Karyopharm Therapeutics, Inc. - Agonox - Tolero Pharmaceuticals, Inc. - AlphaMab Co., Ltd For more information visit http://www.researchandmarkets.com/research/wm...d_and_neck
CVM: 0.63 (+0.01), IMGN: 9.95 (-0.15), AMGN: 161.98 (-0.44), LLY: 67.20 (-0.65), ONTX: 4.77 (-0.08), BMY: 58.60 (-0.12), GSK: 45.76 (-0.20), OXGN: 1.77 (-0.15), XLRN: 32.29 (-1.43), KPTI: 43.00 (unch), NVS: 93.05 (+0.28)
Insider Trading Alert - PX, CDW And BMY Traded By Insiders
at The Street - Mon Nov 10, 10:15AM CST
Stocks with insider trader activity include PX, CDW and BMY
BMY: 58.60 (-0.12), PX: 126.61 (-0.09), CDW: 32.55 (-0.04)
Merck Down On Hepatitis C Data; Gilead Rises
at Investor's Business Daily - Mon Nov 10, 10:14AM CST
Big pharma Merck (MRK) was down nearly 2% on the stock market today after the latest data from its hepatitis C pipeline underwhelmed the Street. On Sunday at the annual conference of the American Association for the Study of Liver Disease, Merck...
JNJ: 108.78 (-0.13), GILD: 106.15 (-1.86), ACHN: 12.99 (+0.51), MRK: 59.40 (+0.03), ABBV: 63.82 (-0.03), BMY: 58.60 (-0.12)
(0)
(0)Bristol-Myers Squibb Company (BMY) Stock Research Links
Scroll down for more posts ▼